Susquehanna International Group, LLP Biomarin Pharmaceutical Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $5.31 Million - $7.22 Million	76,900 Added 38.74%	275,400 $19.4 Million
Q2 2024 Aug 15, 2024	SELL	$74.43 - $92.22 $1.06 Million - $1.32 Million	-14,300 Reduced 6.72%	198,500 $16.3 Million
Q1 2024 May 07, 2024	BUY	$83.81 - $99.0 $4.07 Million - $4.81 Million	48,600 Added 29.6%	212,800 $18.6 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $3.94 Million - $5.09 Million	51,700 Added 45.96%	164,200 $15.8 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $9.26 Million - $10.3 Million	-108,800 Reduced 49.16%	112,500 $9.95 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $2.22 Million - $2.57 Million	-25,600 Reduced 10.37%	221,300 $19.2 Million
Q1 2023 May 16, 2023	BUY	$87.74 - $117.27 $2.13 Million - $2.85 Million	24,300 Added 10.92%	246,900 $24 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $11.6 Million - $15.6 Million	143,300 Added 180.71%	222,600 $23 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.17 Million - $1.39 Million	14,300 Added 22.0%	79,300 $6.72 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.